In this study, we aimed at assessing for the first time CSF selenoprotein P content in vivo in patients with newly diagnosed ALS, AD and MCI as well as in controls and at characterizing the possible involvement of CSF and blood selenoprotein P concentrations in the etiology and the progression of these neurodegenerative diseases. The gene discussed is SELENOP; the disease is Alzheimer disease.